Conditions: Relapsing-Remitting Multiple Sclerosis
Keywords: relapsing oral remitting multiple sclerosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1234
Healthy volunteers: no

Brief summary:
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse.

The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.

Detailed description:

Arms:
arm 1: Participants received two placebo capsules orally three times daily (TID) arm 2: Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD) arm 3: Participants received two 120 mg BG00012 capsules orally three times daily (TID)

Interventions: intervention 1: BG00012 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: